Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-07-29
2008-07-29
Bunner, Bridget E. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S193100, C530S350000, C514S002600, C435S069100
Reexamination Certificate
active
07404957
ABSTRACT:
This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
REFERENCES:
patent: 5986059 (1999-11-01), Shanafelt et al.
patent: 6130318 (2000-10-01), Wild et al.
patent: 6608183 (2003-08-01), Cox, III
patent: WO 98/03654 (1998-01-01), None
Kips et al. European Respiratory Journal, 2001. vol. 17, pp. 499-506.
Ying S., et al., “Expression of IL-4 and IL-5 mRNA and Protein Product by CD4+and CD8+T Cells, Eosinophils, and Mast Cells in Bronchial Biopsies Obtained from Atopic and Nonatopic (Intrinsic) Asthmatics,”J. Immunol., 158(7):3539-3544 (Apr. 1, 1997).
Huang S., et al., “IL-13 Expression at the Sites of Allergen Challenge in Patients with Asthma,”J. Immunol., 155(5):2688-2694 (Sep. 1, 1995).
Zhu Z., et al., “Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production,”J: Clin. Invest., 103(6):779-788 (Mar. 1999).
Henderson W., et al., “Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma,”J. Immunol., 164(2):1086-1095 (Jan. 15, 2000).
Levens JM, et al., “Micro-environmental factors in the survival of human B-lymphoma cells,”Cell Death Differ., 7:59-69 (2000).
Myers J., et al., “Growth Stimulation of Human Head and Neck Squamous Cell Carcinoma Cell Lines by Interleukin 4,”Clin Cancer Res., 2:127-135 (Jan. 1996).
Newcom Sr, et al., “Interleukin-4 Is an Autocrine Growth Factor Secreted by the L-428 Reed-Sternberg Cell,”Blood, 79(1):191-197 (Jan. 1, 1992).
Gee K., et al., “Differential Effect of IL-4 and IL-13 on CD44 Expression in the Burkitt's Lymphoma B Cell Line BL30/B95-8 and in Epstein-Barr Virus (EBV) Transformed Human B Cells: Loss of IL-13 Receptors on Burkitt's Lymphoma B Cells,”Cell Immunol., 211:131-142 (2001).
Kryworuchko M., et al., “Regulation of CD44-Hyaluronan Interactions in Burkitt's Lymphoma and Epstein-Barr Virus-Transformed Lymphoblastoid B Cells by PMA and Interleukin-4,”Cell Immunol., 194:54-66 (1999).
Kruse N., et al., “Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement,”Embo J., 11(9):3237-3244 (1992).
Tony H., et al., “Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency ,”Eur. J. Biochem., 225:659-665 (1994).
Kreitman, et al., “Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity,”Biochem. 33:11637-11644, (1994).
Greve Jeffrey Michael
Longphre Malinda
Pan Clark
Roczniak Steve
Tomkinson Adrian
Aerovance, Inc.
Bunner Bridget E.
DLA Piper (US) LLP
Hamud Fozia M
LandOfFree
Modified IL-4 mutein receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified IL-4 mutein receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified IL-4 mutein receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766960